Clopidogrel Response — CYP2C19 variants determine whether the world's most prescribed antiplatelet drug activates in your body or passes through it unchanged.
The FDA boxed warning on clopidogrel explicitly references CYP2C19 poor metabolizer status. Whole genome sequencing provides complete CYP2C19 diplotype for definitive prescribing guidance — the same information cardiologists need before stenting.
Clopidogrel (Plavix) Response
Clopidogrel (Plavix) is a thienopyridine prodrug that requires hepatic bioactivation to its active thiol metabolite by cytochrome P450 2C19 (CYP2C19). The active metabolite irreversibly inhibits the platelet P2Y12 ADP receptor, reducing platelet aggregation and preventing arterial thrombus formation. Clopidogrel is prescribed to more than 70 million patients annually worldwide — primarily for secondary prevention after acute coronary syndrome, dual antiplatelet therapy following percutaneous coronary intervention (PCI) with stent placement, prevention of recurrent stroke, and peripheral arterial disease management.
CYP2C19 metabolizer status directly determines clopidogrel's clinical effectiveness. CYP2C19 poor metabolizers (PMs) — those who carry two loss-of-function alleles, most commonly *2 (rs4244285) and *3 (rs4986893) — cannot convert clopidogrel to its active form at therapeutic rates. In landmark studies including TRITON-TIMI 38 and PLATO, CYP2C19 loss-of-function carriers had a 50-57% relative increase in major adverse cardiac events (MACE) — including stent thrombosis, myocardial infarction, and cardiovascular death — compared to extensive metabolizers. The FDA added a boxed warning to clopidogrel in 2010 explicitly recommending CYP2C19 genotyping and dose adjustment or alternative antiplatelet therapy in poor metabolizers.
CYP2C19 metabolizer phenotypes span a spectrum: ultra-rapid metabolizers (*17/*17 or *17/normal function allele) convert clopidogrel at above-normal rates and may be at elevated bleeding risk; rapid metabolizers carry one *17 allele paired with a normal function allele; extensive metabolizers (the reference standard) carry two normal function alleles; intermediate metabolizers carry one loss-of-function allele; and poor metabolizers carry two loss-of-function alleles. The CPIC guideline (Level A — highest evidence) recommends an alternative antiplatelet agent (prasugrel or ticagrelor) for CYP2C19 intermediate and poor metabolizers undergoing PCI, with particularly strong guidance for poor metabolizers in the acute coronary syndrome setting.
CYP2C19 *2 and *3 are the most common loss-of-function variants but at least 35 star alleles have been defined. Allele frequencies vary substantially by ancestry — *2 frequency ranges from ~15% in Europeans to ~30% in East Asians.
Point-of-care CYP2C19 tests and standard pharmacogenomics panels check a fixed set of variants. Whole genome sequencing reads the complete CYP2C19 sequence — including rare functional variants and ancestry-specific alleles that fixed panels miss.
The CYP2C19 allele affecting your clopidogrel response may not be on the standard panel
Commercial pharmacogenomics panels and point-of-care cardiac genotyping tests are designed to detect the most common CYP2C19 variants — primarily *2 and *3. CPIC-defined star alleles include at least 35 variants with functional consequences, and rare loss-of-function variants (*4 through *8) and gain-of-function variants (*17 subtypes) are not interrogated by most panels. Studies have documented clinically significant CYP2C19 variants in patients who tested 'normal' on standard limited panels. Whole genome sequencing reads the complete CYP2C19 gene sequence and surrounding regulatory regions, capturing all defined star alleles including rare functional variants that fixed-content panels miss.
Your cardiologist needs an actionable diplotype before prescribing, not a variant list
The CPIC Level A guideline for clopidogrel and CYP2C19 translates genotype into a prescribing recommendation: extensive metabolizers → clopidogrel standard dosing; intermediate metabolizers → consider alternative antiplatelet; poor metabolizers → use prasugrel or ticagrelor. This diplotype-level interpretation requires knowing both alleles across the complete CYP2C19 gene. The Dante pharmacogenomics report delivers CYP2C19 diplotype and metabolizer class in a physician-ready format — the same information required to implement the FDA boxed warning and CPIC guideline at the point of prescribing.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Clopidogrel (Plavix) Response and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
